首页> 外文期刊>Infection and immunity >Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+ T-Cell Responses
【24h】

Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+ T-Cell Responses

机译:腺病毒和修饰的痘苗病毒安卡拉载体的初免-加强免疫增强了保护性疟疾CD8 + T细胞反应的持久性和多功能性。

获取原文
           

摘要

Protection against liver-stage malaria relies on the induction of high frequencies of antigen-specific CD8+ T cells. We have previously reported high protective levels against mouse malaria, albeit short-lived, by a single vaccination with adenoviral vectors coding for a liver-stage antigen (ME.TRAP). Here, we report that prime-boost regimens using modified vaccinia virus Ankara (MVA) and adenoviral vectors encoding ME.TRAP can enhance both short- and long-term sterile protection against malaria. Protection persisted for at least 6 months when simian adenoviruses AdCh63 and AdC9 were used as priming vectors. Kinetic analysis showed that the MVA boost made the adenoviral-primed T cells markedly more polyfunctional, with the number of gamma interferon (INF-γ), tumor necrosis factor alpha (TNF-α), and interleukin-2 (IL-2) triple-positive and INF-γ and TNF-α double-positive cells increasing over time, while INF-γ single-positive cells declined with time. However, IFN-γ production prevailed as the main immune correlate of protection, while neither an increase of polyfunctionality nor a high integrated mean fluorescence intensity (iMFI) correlated with protection. These data highlight the ability of optimized viral vector prime-boost regimens to generate more protective and sustained CD8+ T-cell responses, and our results encourage a more nuanced assessment of the importance of inducing polyfunctional CD8+ T cells by vaccination.
机译:预防肝期疟疾依赖于高频诱导抗原特异性CD8 + T细胞。我们以前曾报道过,通过短暂接种编码肝阶段抗原(ME.TRAP)的腺病毒载体,可以短期抵抗小鼠疟疾,尽管这种保护作用是短暂的。在这里,我们报告使用改良牛痘病毒安卡拉(MVA)和编码ME.TRAP的腺病毒载体的初免-加强疗法可以增强针对疟疾的短期和长期无菌保护。当猿猴腺病毒AdCh63和AdC9用作启动载体时,保护作用持续至少6个月。动力学分析表明,MVA增强使腺病毒引发的T细胞具有更多的功能,γ干扰素(INF-γ),肿瘤坏死因子α(TNF-α)和白介素2(IL-2)的数量增加了三倍。阳性和INF-γ和TNF-α双阳性细胞随时间增加,而INF-γ单阳性细胞随时间下降。但是,IFN-γ的产生是保护的主要免疫相关因素,而多官能度的提高或高平均平均荧光强度(iMFI)均与保护无关。这些数据凸显了优化的病毒载体初免-加强方案产生更多保护性和持续性CD8 + T细胞反应的能力,我们的结果鼓励对疫苗接种诱导多功能CD8 + T细胞的重要性进行更细致的评估。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号